Intismeran autogene plus pembrolizumab cut the risk of recurrence or death by 42% vs pembrolizumab alone in resected stage IIB-IV melanoma.
|Videos|April 4, 2019
Entinostat Plus Pembrolizumab Shows Promise in Previously Treated Melanoma
Author(s)Ryan J. Sullivan, MD
Cancer Network spoke with Ryan J. Sullivan, MD, about the efficacy and safety of entinostat plus pembrolizumab in patients previously treated with immunotherapy.
Advertisement
Cancer Network spoke with Ryan J. Sullivan, MD, about the efficacy and safety of entinostat plus pembrolizumab in patients previously treated with immunotherapy.
Advertisement
Related to this article
Cosibelimab is now a preferred, category 2A NCCN option for locally advanced CSCC when curative surgery or radiation is not feasible.
Advertisement
Advertisement
Trending on CancerNetwork
1
Intismeran Plus Pembrolizumab Reduces Recurrence Risk in Resected Melanoma
2
What Pope Leo XIV’s Lung Cancer Diagnosis Could Mean for Stigma & Nihilism
3
Zipalertinib May Introduce Another Option to EGFR Exon 20+ NSCLC
4
Rethinking Patient Selection Strategy for Phase 1 Breast Cancer Trials
5